Consequently, the European Society for Medical Oncology recommends routine EGFR-mutation profiling for NSCLC patients to guide the prescription of selective EGFR-TKIs for those with TKI-sensitive mutations [6]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.